Instituto de Física, Universidade Federal de Goiás, Goiânia, GO, Brazil.
J Pharm Sci. 2013 May;102(5):1661-9. doi: 10.1002/jps.23496. Epub 2013 Mar 1.
Miltefosine (MT) is an alkylphospholipid that has been approved for the treatment of breast cancer metastasis and visceral leishmaniasis, although its mechanism of action remains poorly understood. Electron paramagnetic resonance spectroscopy of a spin-labeled lipid and a thiol-specific spin label showed that MT causes an increase in the molecular dynamics of erythrocyte ghost membranes and detergent-resistant membranes (DRMs) prepared from erythrocyte ghosts. In the vesicles of lipid raft constituents, it was shown that 20 mol % sphingomyelin could be replaced by 20 mol % MT with no change in the molecular dynamics. The effect of MT in DRMs was more pronounced than in erythrocyte ghosts, supporting the hypothesis that MT is a lipid raft modulator. At the reported MT-plasma concentrations found during the treatment of leishmaniasis (31-90 µg/mL), our measurements in the blood plasma indicated a hemolytic level of 2%-5%. The experiments indicated that MT acts predominantly on the protein component of the membrane. MT aggregates may wrap around the hydrophobic polypeptide chains, forming micelle-like structures that stabilize protein conformations more exposed to the solvent. Proteins with higher hydrophobicity may induce the penetration of the hydrophilic groups of MT into the membrane and cause it to rupture.
米替福新(MT)是一种烷基磷脂,已被批准用于治疗乳腺癌转移和内脏利什曼病,尽管其作用机制仍不清楚。用自旋标记脂质和巯基特异性自旋标记的电子顺磁共振光谱表明,MT 导致红细胞胞膜和从红细胞胞膜制备的去污剂抗性膜(DRMs)的分子动力学增加。在脂质筏成分的囊泡中,表明 20mol%的神经鞘磷脂可以被 20mol%的 MT 取代,而分子动力学没有变化。MT 在 DRMs 中的作用比在红细胞胞膜中更为明显,这支持了 MT 是一种脂筏调节剂的假说。在报道的利什曼病治疗期间(31-90μg/ml)发现的 MT-血浆浓度下,我们在血浆中的测量表明溶血水平为 2%-5%。实验表明 MT 主要作用于膜的蛋白质成分。MT 聚集物可能包裹在疏水性多肽链周围,形成类似胶束的结构,使更多暴露于溶剂的蛋白质构象稳定。疏水性更高的蛋白质可能会诱导 MT 的亲水区进入膜并导致其破裂。